DUBLIN – Lyxumia (lixisenatide), the glucagon-like peptide 1 (GLP-1) agonist, which Zealand Pharma A/S out-licensed to Sanofi SA, is on track for a third-quarter new drug application (NDA) filing, following a cardiovascular safety study in which the drug had a similar profile to placebo.